No Data
No Data
Express News | ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.59%
ZyVersa Therapeutics Announces Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
Publication showed that IC 100 suppressed retinal microglia activation by interfering with ASC speck formation, attenuating retinal inflammation, abnormal retinal vascularization, and retinal thinning, and it led to
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to Be Held Virtually on July 15, 2024
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and
Peering Into ZyVersa Therapeutics's Recent Short Interest
ZyVersa Therapeutics's (NYSE:ZVSA) short percent of float has fallen 96.61% since its last report. The company recently reported that it has 15 thousand shares sold short, which is 2.06% of all regula
Express News | Zyversa Therapeutics: Inflammasome Asc Inhibitor Ic 100's Preclinical Program Nearing Completion, Glp Toxicology Studies Expected to Begin H1-2024
Express News | ZyVersa Therapeutics Q1 2024 Adj EPS $(4.53) Misses $(3.70) Estimate
No Data